1 / 7

Firalis SAS

Biomarker R&D Bridging Science to Clinics 12 Juin 2009 Maison de la Région Alsace – Strasbourg Hüseyin FIRAT, President, CSO. Firalis SAS. Firalis at a Glance. Our Mission Creating novel values in biomarker (BM)-based diagnostics via R&D and regulatory qualification of BMs

mora
Download Presentation

Firalis SAS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Biomarker R&D Bridging Science to Clinics 12 Juin 2009 Maison de la Région Alsace – Strasbourg Hüseyin FIRAT, President, CSO Firalis SAS

  2. Firalis at a Glance Our Mission Creating novel values in biomarker (BM)-based diagnostics via R&D and regulatory qualification of BMs Focus of Interest BMs of inflammatory cardiovascular diseases Two-pillar business model Servicing activities European contract approved >3 Mio € for 5 years Biomarker R&D activities Companion Diagnostic Test – IP secured Disease Biomarkers – IP secured President:Hüseyin FIRAT Legal Status:SAS founded in July 2008 Location:Huningue, South-Alsace, proximity of Basel/Switzerland Firalis Firalis proprietary information

  3. Start-up Team Management team Jean-Claude Wehrle CEO, from Sept 2009, Former CEO of NanoVivoDiagnostics Corporation Hueseyin Firat, MD, PhD, Founder President, CSO Attila Garami MD, PhD, Director of Translational BMs&IA Fidan Aras MD, Responsible for Assay Development Fuat Firat Management, responsible for Financial Affairs Béatrice Molac PhD, Director of Regulatory Affairs & PI Stella Suzan PhD, Project Manager Consultant support: Denis le Bouteiller MSc, MBA, Management Brice Suire Senior Financial Advisor Joerg Staeheli DMan, Business Strategy Advisor IMI-JU service provider Interface EuropeLandry Cochard (Bruxelles) Firalis Firalis proprietary information

  4. Servicing Activities Services offered by Firalis Strategy consulting in BM R&D,support establishment of R&D programs, from design to clinical qualification Management of BM R&D,upto the qualification of BMs. A part of experimental work is subcontracted Integrative analysis of data from clinicaland/or x-omicBM studies Development of BM assays and preclinical/clinical sample testing Meso-Scale Discovery Platform Firalis Firalis proprietary information

  5. IMI-JU (Call #2008.1.5) Firalis has created and coordinated the SAFE-T (Safer And Faster Evidence-based Translation) consortium Development of Translational Safety BMs (liver, kidneys and vascular system) Overall foreseen budget: 36 Mio € over 5 years 11 «major pharmas», 4 biotechs, 6 academic EMEA1 (as partner) and FDA2 (as advisor) Firalis 1European Medicines Agency 2Food and Drug Administration, USA 3Europeen Federation of Pharmaceutical Industry and Associations 5 Firalis proprietary information

  6. IMI-JU (Call #2008.1.5) Firalis is a major contributor to SAFE-T Initiator of the SAFE-T project and coordinator of applicant consortium Co-leading with the Industry partners 4 out of 9 Work Packages Obtained the highest EU funding among all partners Unique SME within the vascular project (budget:12 Mio €, 7 Mio € EFPIA3 contribution) Firalis 3European Federation of Pharmaceutical Industry and Associations 6 6 Firalis proprietary information

  7. Acknowledgement Firalis • Firalis team acknowledges for their support • Regional institutions • Agence Régionale de l’Innovation (JJ Bernardini) • SEMIA, • OSEO Alsace, • Alsace Biovalley • Philippe ARHETS, PCN Santé • IMI-JU service provider • Interface Europe, Bruxelles (Landry Cochard) 7 7 Firalis proprietary information

More Related